Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care

Bristol Myers Squibb unveils breakthrough Lymphoma data

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

NHS’s breakthrough leukaemia therapy set to transform lives in UK

Clinical trials found that 77% of patients went into remission after receiving obe-cel

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial